Immunoglobulin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-Resistant Plasmodium falciparum in Gambian Children

Margaret Pinder, Colin J. Sutherland, Fatoumatta Sisay-Joof, Jamila Ismaili, Matthew B. B. McCall, Rosalyn Ord, Rachel Hallett, Anthony A. Holder and Paul Milligan


Updated information and services can be found at:
http://iai.asm.org/content/74/5/2887

These include:
REFERENCES
This article cites 38 articles, 21 of which can be accessed free at:
http://iai.asm.org/content/74/5/2887#ref-list-1

CONTENT ALERTS
Receive: RSS Feeds, eTOCs, free email alerts (when new articles cite this article), more»
Immunoglobin G Antibodies to Merozoite Surface Antigens Are Associated with Recovery from Chloroquine-Resistant Plasmodium falciparum in Gambian Children

Margaret Pinder,1* Colin J. Sutherland,3 Fatoumatta Sisay-Joof,1 Jamila Ismaili,1 Matthew B. B. McCall,2 Rosalyn Ord,3 Rachel Hallett,3 Anthony A. Holder,4 and Paul Milligan1,3

Medical Research Council Laboratories, Banjul, The Gambia1; University of Nijmegen, Nijmegen, The Netherlands2; London School of Hygiene and Tropical Medicine, London, United Kingdom3; and Division of Parasitology, National Institute for Medical Research, Mill Hill, London, United Kingdom4

Received 15 June 2005/Returned for modification 26 August 2005/Accepted 22 February 2006

We examined the hypothesis that recovery from uncomplicated malaria in patients carrying drug-resistant Plasmodium falciparum is a measure of acquired functional immunity and may therefore be associated with humoral responses to candidate vaccine antigens. Gambian children with malaria were treated with chloroquine in 28-day trials, and recovery was defined primarily as the absence of severe clinical malaria at any time and absence of parasitemia with fever after 3 days. Plasma samples from these children were assayed by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) to recombinant merozoite antigens: apical membrane antigen 1 (AMA-1) and the 19-kDa C-terminal region of merozoite surface protein 1 (MSP-119), including antigenic variants of MSP-119 with double and triple substitutions. Antigen-specific IgG was more frequent in children who recovered, particularly that for MSP-119 (age-adjusted odds ratios: 0.32 [95% confidence interval, 0.05, 1.87; \( P = 0.19 \)) for AMA-1, 0.19 [0.03, 1.11; \( P = 0.019 \)] for recombinant MSP-119, 0.24 [0.04, 1.31; \( P = 0.032 \)] for the recombinant MSP-119 double variant, and 0.18 [0.03, 0.97; \( P = 0.013 \)] for the triple variant). IgG titers to MSP-119 and to the triple variant were higher in plasma samples taken 7 days after chloroquine treatment from children who carried resistant parasites but recovered and remained parasite free. Moreover, in children who were parasitemic on day 14 or day 28, there was an age-independent relationship between parasite density and IgG to both MSP-119 and the triple variant (coefficients of −0.550 and −0.590 and \( P \) values of 0.002 and 0.001, respectively). The results validate the use of this approach to identify antigens that are associated with protection from malaria.

The development of a malaria vaccine is increasingly important in the face of the growing worldwide threat of the disease (29, 35). Since vaccine-induced immune responses are often short-lived, many vaccine strategies aim to elicit protective immune responses that may be boosted by subsequent exposure to natural infection. Such responses are commonly identified by longitudinal cohort studies. Residents of an area where malaria is endemic are sampled for a particular immune response and then monitored for parasite infection or disease over the next few months to determine susceptibility (18, 27, 32, 33). In such studies, functional immunity may be defined as the result of a lower probability of developing clinical malaria, high parasite levels, or infection. Disadvantages of this method include the following. (i) Exposure to infection is an important confounder but is difficult to measure. (ii) The time between baseline sampling and endpoint detection allows immune responses to wax or wane, possibly depending on subclinical or microscopically subpatent infection rates. (iii) The burden of such studies is high in terms of both participant inconvenience and research costs. Alternative ways of identifying individuals with functional protective immunity could greatly improve our ability to evaluate parasite antigens as vaccine candidates.

Three studies have investigated the relationship between antibody and therapeutic success in malaria patients. In Senegal (34) and Thailand (24), antibody responses to the repetitive circumsporozoite protein antigen and ring erythrocyte surface antigen, respectively, were shown to be more prevalent in patients who recovered than in patients with treatment failure. The third study, in Gabon (23), showed no association between outcome and antibody responses to several recombinant merozoite surface protein 1 (MSP-1) polypeptides, including the conserved 19-kDa C-terminal MSP-119, although there was an association with antibody to K1 and MAD 20 allelic families of the MSP-1 block 2 region. Although acquired immune responses may be more important in drug-resistant infections, parasite genotypes were not determined. Mutations in the Pfcrtp and Pfmdrl genes are associated with resistance to chloroquine (CQ), but the Pfcrtp-76Thr variant appears most strongly associated with CQ resistance in all populations examined so far (9, 36, 38). In addition, in Malawi, the prevalence of the Pfcrtp-76Thr variant decreased in the parasite population after CQ treatment was discontinued, while that of the Pfmdrl-86Tyr variant remained unchanged (28).

In much of West Africa, where CQ monotherapy has been the first-line therapy for uncomplicated malaria, treatment failure rates tend to be lower among older children (10), and a similar tendency is seen even when resistance to the treatment drug is very low (13); these observations may reflect a contribution from acquired immunity. Djimdé and colleagues (11) therefore proposed that treatment response is a phenotype for
identifying host responses that provide protective immunity against malaria. Elimination of parasites by the immune system requires effectors that target blood-stage asexual parasites, and B cells and antibodies are known to play a key role in protective immunity against these stages, as shown by passive immunization studies with mice and humans (8, 21, 25).

Antibodies may act in a variety of ways, for example by preventing merozoite invasion of erythrocytes, by attacking infected erythrocytes, probably in conjunction with monocytes, or by preventing cytoadhesion of infected erythrocytes (19). Molecules important to all three of these processes have been identified as candidate vaccines, but those involved in merozoite invasion have been the most studied. Several merozoite surface molecules are well characterized (e.g., MSP-1 to -9, erythrocyte binding antigen-175, and apical merozoite antigen 1 [AMA-1]). There is evidence to implicate antibodies from malaria-immune donors in the inhibition of parasite invasion of erythrocytes, especially antibodies specific for MSP-1/9 (2, 20) and the ectodomain of AMA-1 (recently reviewed in reference 32). Some cohort studies have shown that the presence of antibody to MSP-1 is associated with lower rates of clinical malaria in the following high-transmission season (1, 15), although other studies (e.g., reference 12) found no such association. Similarly, evidence for a protective role for AMA-1 in vivo had been elusive until a recent cohort study showed an association of antibodies to the ectodomain, with protection from clinical malaria in Kenyans (32). This variation in results may reflect limitations in the cohort method as outlined above or the need for a more precise definition of the antibody. For example, the fine specificity of MSP-1/9 antibodies, together with their prevalence and titer level, may better predict protection (30, 31, 39). Some MSP-1/9-specific antibodies actually block the binding of protective antibodies, highlighting the need to measure functional antibody (20).

We hypothesized that following drug treatment, antibodies to these merozoite surface molecules play a role in the elimination of Plasmodium falciparum in areas where drug resistance is highly prevalent. In 2000 and 2001, pediatric treatment trials for uncomplicated malaria conducted in The Gambia included CQ comparison arms (14, 37). We have used plasma and data from these trials and examined whether antibodies to AMA-1 and MSP-1/9 are associated with clinical recovery and elimination of parasites. Three forms of MSP-1/9 were used as antigens: a naturally occurring sequence and two variants that have been modified to reduce the binding of blocking antibodies (20).

**MATERIALS AND METHODS**

**Study population and samples.** During the 2000 and 2001 malaria high-transmission seasons, children of 1 to 10 years of age attending Farafenni MCH clinic with symptoms of uncomplicated malaria were screened, and eligible children were invited to participate in a clinical trial of antimalarial drug treatment. Two hundred fifty-three children (130 in 2000 and 123 in 2001) were treated with CQ and followed for 28 days after treatment. Parasites were quantified by microscopy examination of Giemsa-stained thick blood smears (16). Children lost to follow-up were excluded, since their response to treatment could not be classified, leaving 46 day 0 and 44 day 7 plasma samples, 12 of which were from the same children, for analysis.

To compare antibody responses in the malaria cases with those in healthy children, control samples were selected from those taken in a cross-sectional community-based survey of children in the study area shortly before the start of the 2000 high-transmission season and frequency matched by age to the malaria cases in 1-year age bands. These studies were approved by the Joint Gambian Government/MRC Ethics Committee.

**Parasite genotyping.** Extracted DNA was genotyped for Pfert-Thr/Lys by PCR-restriction fragment length polymorphism using methods described previously (9, 36).

**Enzyme-linked immunosorbent assay (ELISA).** The ectodomain of AMA-1 FVO strain expressed in Pichia pastoris was donated by Alan Thomas, BPRC, The Netherlands (22). It was purified by affinity chromatography with nickel resin and ammonium sulfate precipitation and found to be pure by gel electrophoresis. Recombinant MSP-1/9 (wild-type [WT]) Wellcome sequence, accession number P04093 was prepared by standard techniques as a glutathione S-transferase (GST) fusion protein. Two modified MSP-1/9 antigens were also prepared as GST fusion proteins: a triple variant that carries three amino acid substitutions (Glu27 to Tyr, Leu31 to Arg, and Glu43 to Leu) and a double variant with two substitutions (Cys12 to Ile and Cys28 to Trp, which thus lacks a disulfide bond). (Amino acid residues are numbered from Aaa1 at the N terminus of MSP-1/9). Both variants lack one or more epitopes for blocking antibodies (39). GST served as a control for the recombinant MSP-1/9 antigens.

Plasma samples were relabeled so that laboratory staff would be unaware of treatment outcome. ELISAs were conducted as described in references 6 and 32. Antigens were coated onto 96-well polystyrene plates at 1 μg/ml (Immunon 4; Thermo Lab Systems, United Kingdom), and plasma samples were assayed in duplicate at a 1:1,000 dilution. Bound antibodies were detected with a horseradish peroxidase-conjugated rabbit anti-human immunoglobulin G (IgG) (Dako, Glostrup, Denmark) and developed with o-phenylenediamine dihydrochloride substrate (Sigma, United Kingdom).

A positive standard (PS) high-titer adult serum sample was included on every plate, and mean optical densities (ODs) were normalized between assays using the following formula: (OD of sample) × (mean OD of PS)/(mean OD of PS). ODs for the MSP-1/9 recombinants were corrected for the binding of IgG to GST alone. Negative responses for all ELISAs were defined as those below the mean OD + 3 SD of a single batch of 40 individual sera from adults who had never previously visited an area of malaria endemicity. Background mean and SD values for AMA-1 were 0.235 and 0.144, giving a cutoff value of 0.668. For MSP-1/9 antigens, the background mean and SD values for GST, WT, triple variant, and double variant were 0.126 and 0.060, 0.088 and 0.034, 0.073 and 0.029, and 0.090 and 0.033, respectively, giving cutoff values of 0.104, 0.107, and 0.106. Plasma samples positive for the total IgG conjugate were also analyzed with an IgG subclass ELISA by use of sheep anti-human horseradish peroxidase conjugates (The Binding Site, Birmingham, United Kingdom); cutoff values for AMA-1, MSP-1/9, WT, and the triple variant were 0.058, 0.021, and 0.014, respectively, for IgG1 and 0.107, 0.016, and 0.018, respectively, for IgG3. To quantify IgG to MSP-1/9, WT, and the triple variant more precisely, assays were repeated with serial dilutions and antibody concentrations were estimated by comparison to standard curves generated using purified polyclonal human IgG (The Binding Site, United Kingdom) (7).

**Statistical methods.** Statistical analysis was done using STATA version 8 (Stata Corporation, College Station, Texas) and logXact version 6 (Cytel Software Corporation). The primary analysis was a determination of the influence of specific antibody to malaria parasite in plasma taken at enrollment (day 0) on the risk of clinical failure by day 28. Clinical failure was defined as presence of (i) severe malaria on days 1 to 28, (ii) parasitemia and fever (≥37.5°C) on days 3 to 28, and (iii) parasitemia on day 3 >25% of that on day 0 (40). In a secondary analysis, we investigated the association of antibody responses on day 7 with late parasitological failure, defined as parasitemia on day 14 or day 28, and with the density of parasitemia on these days. Children who had neither clinical nor parasitological failure as defined above were considered to have cleared their parasites. CQ-resistant infections were defined as those where the Plf76Thr allele was dominant in the day 0 sample. Characteristics through to potential confounders of the relationship between immunological variables and treatment outcome were age and the presence of drug-resistant parasite genotypes. Odds ratios for treatment failure were calculated with mid-P values, which are less conservative than exact tests, and exact confidence intervals. The two-sample Wilcoxon rank-
Clinical failures occurred soon after treatment, 13/16 (81%) before day 14, and all parasitological failures were detected on day 14 (29/45) or on day 28 (16/45), with a mean detection time point of 18.9 days.

Association of pretreatment IgG with clinical outcome. Prevalence of antibody for each of the antigens was higher in children who did not experience clinical failure than in those that did (Table 2); for example, 6 of the 37 children with detectable pretreatment antibody that recognized WT MSP-1\textsubscript{19} failed treatment, while 5 of the 9 children without such antibody failed treatment. Similar results were obtained for the other proteins: children with antibody to these merozoite antigens were between three and six times as likely to recover without relapse. Odds ratios adjusted for age were similar to unadjusted odds ratios, indicating that age was not a significant confounder in this analysis (Table 2). Antibody titers, estimated as median OD values in responders, were not significantly associated with clinical outcome (results not shown).

Two-thirds (31/46 [67%]) of patients were carrying the Pfcr7-76Thr allele, which is strongly associated with failure of CQ treatment. Although the association between the presence of antibody and treatment outcome appeared to be stronger in the group that had drug-resistant parasite genotypes on day 0, this observation was difficult to test formally because of the small sample size.

There was considerable homogeneity in responder status for the different antigens; only 8 out of the 46 children (17%) were discrepant in their response to AMA-1 and WT MSP-1\textsubscript{19}, and none of these experienced clinical failure. There were discrepancies in responses to the variant MSP-1\textsubscript{19} antigens; two samples were negative for the triple variant alone and one sample was negative for both the triple and double variants while containing antibodies reacting with the wild-type antigen.

Comparison of antibody response in malaria patients and in healthy children. To explore the dynamics of these responses in relation to malarial disease, we compared the prevalence and titers of IgG to AMA-1 and WT MSP-1\textsubscript{19} found in the malaria patients on day 0 to those in clinically normal children sampled before the start of the high-transmission season. As

TABLE 2. Treatment outcome and the presence of IgG to AMA-1 or MSP-1\textsubscript{19} antigens on day 0\textsuperscript{a}

<table>
<thead>
<tr>
<th>Status for indicated antibody on day 0</th>
<th>No. of patients with clinical failure/total (%)</th>
<th>Odds ratio (95% CI; (P) value)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted</td>
<td>Adjusted for age</td>
</tr>
<tr>
<td>AMA-1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>5/11 (45)</td>
<td>1</td>
</tr>
<tr>
<td>Positive</td>
<td>6/35 (17)</td>
<td>0.27 (0.05, 1.46; 0.076)</td>
</tr>
<tr>
<td>WT MSP-1\textsubscript{19}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>5/9 (56)</td>
<td>1</td>
</tr>
<tr>
<td>Positive</td>
<td>6/37 (16)</td>
<td>0.18 (0.03, 1.06; 0.017)</td>
</tr>
<tr>
<td>Triple-variant MSP-1\textsubscript{19}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>6/12 (50)</td>
<td>1</td>
</tr>
<tr>
<td>Positive</td>
<td>5/34 (15)</td>
<td>0.19 (0.03, 0.98; 0.013)</td>
</tr>
<tr>
<td>Double-variant MSP-1\textsubscript{19}</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Negative</td>
<td>6/11 (55)</td>
<td>1</td>
</tr>
<tr>
<td>Positive</td>
<td>5/35 (14)</td>
<td>0.23 (0.04, 1.25; 0.028)</td>
</tr>
</tbody>
</table>

\(\textsuperscript{a}\) Specific IgG was detected by ELISA in plasma from children on day 0 and antibody and therapeutic responses classified as indicated in Materials and Methods. Exact 95% confidence intervals (95% CI) and mid-\(P\) values are given for the crude odds ratios and after adjustment for age.
would be expected in this region of malaria endemicity, almost half (21/46) of the clinically normal children had detectable parasitemia, but the mean parasite density was over 100-fold lower than that in the malaria patients. Prevalence of IgG to these antigens was similar between the groups, but titers varied: anti-MSP-119 titers were significantly higher in the clinical cases (median OD of 0.487 and 25th and 75th percentiles [IQR] of 0.241 and 1.411 versus OD of 2.609 and IQR of 1.745 and 3.352; \( P < 0.0001 \)) for AMA-1, seven of the 27 positive responders cleared their parasitemia, and for the MSP-119 antigens eight of the 30 or 29 positive responders cleared theirs. Samples were tested at a 1:1,000 dilution for all antigens, and median OD values are presented. IgG concentrations for WT and triple-variant MSP-119 antigens were then obtained by titration (see Materials and Methods). \( P \) values were estimated using the two-sample Wilcoxon rank-sum test. ND, not done.

### Table 3. Parasitological outcome and day 7 IgG titers to AMA-1 and MSP-119 variants

<table>
<thead>
<tr>
<th>Antigen</th>
<th>No. in group</th>
<th>Median outcome value (25th, 75th percentiles) in cases of parasitological outcome</th>
<th>OD</th>
<th>Failure</th>
<th>Clearance</th>
<th>( P ) value</th>
<th>IgG concn (ng/ml)</th>
<th>Failure</th>
<th>Clearance</th>
<th>( P ) value</th>
</tr>
</thead>
<tbody>
<tr>
<td>AMA-1</td>
<td>27</td>
<td>3.215 (2.016, 3.843 [0.58]) 3.048 (1.505, 3.341) 0.58</td>
<td></td>
<td>ND</td>
<td>ND</td>
<td>0.057</td>
<td>37.03 (21.89, 67.33 [0.057]) 103.68 (52.22, 402.94) 0.057</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT MSP-119</td>
<td>30</td>
<td>1.980 (1.567, 3.019 [0.083]) 2.648 (2.484, 3.941) 0.083</td>
<td></td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>17.63 (12.00, 49.35 [0.057]) 66.83 (29.95, 300.96) 0.057</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Triple-variant MSP-119</td>
<td>29</td>
<td>1.627 (1.257, 2.730 [0.097]) 2.536 (2.140, 3.745) 0.097</td>
<td></td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>1.497 (1.086, 2.325 [0.223]) 2.416 (1.513, 3.681) 0.223</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Double-variant MSP-119</td>
<td>29</td>
<td>1.497 (1.086, 2.325 [0.223]) 2.416 (1.513, 3.681) 0.223</td>
<td></td>
<td>ND</td>
<td>ND</td>
<td></td>
<td>1.497 (1.086, 2.325 [0.223]) 2.416 (1.513, 3.681) 0.223</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

\( ^{*} \) Specific IgG was detected by ELISA in plasma collected on day 7 from children infected with the Pfcr7-Thr genotype parasite, and results of positive responders are presented according to parasitological failure or clearance. For AMA-1, seven of the 27 positive responders cleared their parasitemia, and for the MSP-119 antigens eight of the 30 or 29 positive responders cleared theirs. Samples were tested at a 1:1,000 dilution for all antigens, and median OD values are presented. IgG concentrations for WT and triple-variant MSP-119 antigens were then obtained by titration (see Materials and Methods). \( P \) values were estimated using the two-sample Wilcoxon rank-sum test. ND, not done.

### Discussion

In this retrospective study, we have investigated whether antibodies to two key \( P. falciparum \) merozoite surface molecules, AMA-1 and MSP-119, are associated with clinical recovery and control of parasitemia in children undergoing treatment for uncomplicated malaria in an area of high prevalence of drug resistance. Anti-MSP-119 antibodies were associated with clinical recovery and control of parasitemia, while the presence of antibodies to AMA-1 was only weakly associated with clinical recovery and not associated with control of parasitemia. If these associations are causal, the results suggest...
that therapeutic responses to malaria treatment can be useful measures of effective clinical immunity.

As this was a retrospective study, selection of samples for analysis was constrained by their availability. This could have caused bias, but we found no difference in age, clinical outcome, or ethnicity between children who provided sera and those who did not. Two of the most likely confounders of the association of antibody and therapeutic response, age and drug-resistant genotype (10), were examined in detail. Age was not associated with anti-MSP119 concentrations in the present study, but the association between treatment outcome and antibody levels on day 0 appeared to be stronger in children infected with parasites carrying the P
crt-76Thr allele. The influence of this confounder was avoided when studying the day 7 responses by restricting the analysis to those carrying the P
crt-76Thr allele. Genetic variations associated with the sickle cell trait (HbS) or ethnicity also influence the occurrence of malaria in African populations, and both appear to be associated with higher antibody response levels to malaria antigens (3, 5). In the present study, no pattern linking therapeutic response or antibody levels and ethnicity was discernible (results not shown), but this, along with the influence of HbS, needs to be studied in a larger group.

Whereas our findings are not incompatible with those of previous studies that have identified AMA-1 and MSP-119 as candidate target antigens for vaccines, we have no specific evidence that antibodies recognizing these proteins are protective. We have shown that children who clinically recover after treatment are more likely to carry antibody recognizing these antigens. Extensive data from studies conducted in vitro, in animal models, and some malaria-exposed populations support AMA-1 as a vaccine candidate (e.g., reference 32); we found that IgG recognizing MSP-119 is more robustly associated with functional immunity than is that recognizing AMA-1. Direct comparisons between these antigens, however, should be made with caution, as they were not expressed in the same vector and the dynamics of the humoral response may vary between antigens. Our findings with MSP-119 agree with other studies linking anti-MSP-119 antibodies and protection from clinical malaria (e.g., references 1 and 15) and with a longitudinal study of Kenyan infants showing a clear relationship between the presence of anti-MSP-119 antibodies and afebrile, as opposed to febrile, infection (4). However, epidemiological evidence of an association of anti-MSP-119 responses with protection from clinical malaria has been conflicting, possibly reflecting the different methodologies that have been employed. The only previous study of anti-MSP-1 antibodies and therapeutic responses (23) found an association between therapeutic success and prevalence of antibody to MSP-1 block 2 antigens but not to MSP-119. This might reflect the lower prevalence of drug resistance in that study (33% compared to 79% for our patients), and stronger associations may be expected among patients infected with drug-resistant parasites. Also, some cohort studies (e.g., reference 12) found no correlation between anti-MSP-119 antibodies and malaria attacks, but our results show that anti-MSP-119 antibody measured during the low-

![Fig. 1. Comparison of IgG concentrations to wild-type MSP-119 and to the triple variant in individual day 7 plasma samples. Variation between the IgG concentration (ng/ml) in day 7 plasma specific for WT and that for triple-variant MSP-119 is shown. Data from 37 subjects were ranked along the x axis according to their responses to the triple variant. ○ and △, WT MSP-119, with △ indicating cases with parasitological failure; ★, triple variant.](http://iai.asm.org/iai.074.2889.f1a.png)
transmission season may not be a good predictor of levels or prevalence during clinical attacks in the high-transmission season. The dynamics of these responses may explain the variable association between anti-MSP-1 antigen antibodies and protection from clinical attacks found in different studies and are worthy of further investigation.

Our results are, as far as we are aware, the first to show an association of parasite density with anti-MSP-1 IgG concentration during a malaria episode. The presence of a biological gradient increases the likelihood of causality and underlines an advantage in the use of therapeutic responses as an assay of functional immunity. It also supports the possibility that anti-MSP-1 IgG is a component of protection in these children. However, the associations we have observed also simply could reflect the higher level of exposure experienced by those children who are semi-immune, and the truly protective components of acquired immunity may be elicited by other antigens or factors we have not examined.

Cohort studies and therapeutic responses to drug treatment studies may measure different aspects of immunity. In cohort studies, functional immunity can be defined as a lower probability of developing clinical malaria, a higher parasitemia level, or infection (15, 32) and thus includes preerythrocytic immune responses against sporozoite and liver stages. The therapeutic approach, on the other hand, can define functional immunity as the ability to recover clinically or to control parasitemia, both of which may differ in mechanism from the ability to maintain parasitemia below clinically significant levels or to prevent infection. The therapeutic approach may thus identify protective mechanisms of greater relevance to reducing the clinical burden of disease. For example, in the current study, the presence of anti-MSP-1 IgG antibodies at consultation was associated with clinical recovery; if the relationship is causal, such antibodies may play a role in reducing child morbidity.

The IgG subclass analysis confirmed results from previous population studies with the IgG1 antibody subclass predominating for both AMA-1 and MSP-19, and with an additional IgG3 response to MSP-19 (7, 32). The relative balance of antibody binding to the wild-type and triple-variant MSP-19 supports the hypothesis that one or more epitopes on the wild-type antigen are recognized by some malaria-exposed individuals but not by others (30). Future studies could examine the association between differences in antibody fine specificity and clinical outcome. The similarities in IgG responses in patients with malaria and in clinically well, malaria-exposed populations, together with the associations between therapeutic and IgG responses, are consistent with results obtained by use of several other approaches. These similarities indicate that the current methods could be usefully applied to analyze other antigens.

Antimalarial drug treatment policy in sub-Saharan Africa requires accurate data on the degree and distribution of drug resistance in the parasite population, data that are typically generated from in vivo therapeutic efficacy studies. Collaboration on future therapeutic efficacy studies to allow collection of plasma from well-characterized patients may thus be possible, and this approach has been suggested as an ethical alternative to population-based studies (11). A recent review suggests that the number of available antigens is not a rate-limiting step for vaccine development (29) and that a better definition of the antigens we already have, for example an analysis using the modified MSP-1 antigen as shown here, might be an efficient approach to define the antigenic components of effective malaria vaccines.

In conclusion, our results demonstrate that the presence of IgG to AMA-1 and MSP-19 on the day of consultation may protect against clinical failure, and that higher titers of IgG to MSP-19 enhance the likelihood of parasitological clearance in individuals treated with a suboptimal drug regimen; they therefore support the use of therapeutic response studies to characterize candidate vaccine antigens.

ACKNOWLEDGMENTS
This work was supported by the MRC, United Kingdom, by the Wellcome Trust through project no. 061910 (awarded to C.J.S.), and by the European Commission through the EUROMALVAC Consortium, contract QLK2-CT-2002-01197.

We thank all the children and their caregivers for participation in these studies. We thank Simon Correa for expert laboratory assistance; Kalifa Bojanga, Sam Duno, Chris Drakeley, and Geoffrey Targett for access to data and samples from their clinical trials; Terry Scott-Finigan for preparing the MSP-1 antigens; Alan Thomas for generously providing the AMA-1; Paul Snell for assistance with data management; David Jeffries for statistical advice; and Hilton Whittle for useful discussions.

REFERENCES


Editor: J. F. Urban, Jr.